PentoxifyllinePentoxifylline
MedChemExpress (MCE)
HY-B0715
6493-05-6
BL-191
PTX
Oxpentifylline
99.92%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.
Pentoxifylline (0.1-50 mM
24-48 hours) inhibits cell proliferation in a dose-dependent manner[3]. Pentoxifylline (0.5 mM
12-36 hours) increases apoptosis and decreases autophagy levels in MDA-MB-231 cells[3]. Pentoxifylline (0.5 mM
12-36 hours) induces autophagy in MDA-MB-231 cells[3]. Pentoxifylline (0.5 mM
24-48 hours) blocks cell cycle at the G0/G1 phase[3]. Pentoxifylline results in high LC3-II/LC3-ratio[3].
Pentoxifylline (200 mg/kg
i.p.) has a protective effect on rats with transient global ischemia and reduces cognitive impairment[4].
PDE[1] Cellular Effect Cell Line Type Value Description References
| | | |
| | | | | |
[1]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec
5(4): 510–516. [Content Brief]
[2]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul
34(1):50-97. [Content Brief]
[3]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr
52(4):1246-1254. [Content Brief]
[4]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct
15(5): 1083-1090. [Content Brief]